Sage Therapeutics, Inc.

Historical 13F Holders

Symbol
SAGE
CUSIP
78667J108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 78667J108 since 12/18/2024, newest first.

Filer % of Class Filed
Madison Avenue Partners, LP 13G/A Amendment 2
0% 11/14/2025
Event 9/30/2025
Madison Avenue Partners, LP 13G/A Amendment 1
9.7% 8/14/2025
Event 6/30/2025
Biogen Inc. 13D/A Amendment 2
0% 7/30/2025
Event 7/30/2025
Vanguard Group Inc 13G/A Amendment 12 5.2% 7/29/2025
Event 6/30/2025
Biogen Inc. 13D/A Amendment 1
10.0% 7/21/2025
Event 7/21/2025
BlackRock, Inc. 13G/A Amendment 3 7.2% 4/17/2025
Event 3/31/2025
Madison Avenue Partners, LP 13G
8.0% 4/1/2025
Event 3/25/2025
FMR LLC 13G/A Amendment 16
0.8% 3/7/2025
Event 2/28/2025
Morgan Stanley 13G/A Amendment 1
1.6% 3/6/2025
Event 2/28/2025
RTW Investments, LP 13G/A Amendment 1
4.9% 2/14/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 15
6.7% 2/12/2025
Event 12/31/2024
Morgan Stanley 13G
7.4% 2/5/2025
Event 12/31/2024
Vanguard Group Inc 13G/A Amendment 11 7.9% 1/31/2025
Event 12/31/2024
BB Biotech AG 13G/A Amendment 3
1.9% 1/17/2025
Event 1/13/2025
Biogen Inc. 13D
10.2% 1/10/2025
Event 1/10/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 1.00 $9.00
2026 Q1 1 1.00 $9.00
2025 Q4 2 22.2 k $460 k
2025 Q3 5 56.4 k $494 k
2025 Q2 210 51.9 M $473 M
2025 Q1 208 51.8 M $412 M
2024 Q4 186 51.2 M $278 M
2024 Q3 190 51.6 M $375 M
2024 Q2 211 56.1 M $609 M
2024 Q1 222 62.2 M $1.17 B
2023 Q4 223 59.1 M $1.28 B
2023 Q3 217 59.1 M $1.22 B
2023 Q2 251 54.9 M $2.58 B
2023 Q1 234 53.2 M $2.23 B
2022 Q4 230 54.4 M $2.55 B
2022 Q3 223 52.4 M $2.05 B
2022 Q2 228 51.1 M $1.65 B
2022 Q1 236 50.7 M $1.68 B
2021 Q4 249 50.4 M $2.14 B
2021 Q3 247 49.1 M $2.17 B
2021 Q2 288 50.7 M $2.88 B
2021 Q1 293 53.1 M $3.97 B
2020 Q4 277 54.2 M $4.69 B
2020 Q3 258 53.7 M $3.28 B
2020 Q2 247 54.3 M $2.26 B
2020 Q1 256 56.3 M $1.62 B
2019 Q4 309 56.6 M $4.09 B
2019 Q3 324 59.0 M $8.30 B
2019 Q2 317 58.2 M $10.7 B
2019 Q1 302 56.9 M $9.04 B
2018 Q4 291 50.2 M $4.81 B
2018 Q3 310 50.4 M $7.12 B
2018 Q2 295 48.8 M $7.64 B
2018 Q1 273 47.9 M $7.70 B
2017 Q4 257 44.1 M $7.26 B
2017 Q3 207 39.4 M $2.46 B
2017 Q2 224 38.4 M $3.06 B
2017 Q1 223 37.9 M $2.69 B
2016 Q4 185 36.9 M $1.88 B
2016 Q3 168 37.8 M $1.74 B
2016 Q2 170 30.2 M $920 M
2016 Q1 151 29.7 M $953 M
2015 Q4 146 23.6 M $1.38 B
2015 Q3 144 28.0 M $1.20 B
2015 Q2 131 26.4 M $1.93 B
2015 Q1 93 21.5 M $1.08 B
2014 Q4 74 20.3 M $736 M
2014 Q3 53 18.9 M $596 M